Kornimate/medical-research-clean huggingface dataset:
inguinal hernia repair and male fertility

Conditions: Inguinal Hernia Bilateral

Summary: general objective: to evaluate the fertility of adult men submitted to bilateral herniorrhaphy with mesh placement by the lichtenstein and laparoscopic approaches

specific objectives: to correlate pre and postoperative data (90 and 180 days) of adult men, according to biochemistry parameters (hemogram and crp), autoimmune (anti-sperm antibodies), hormonal (fsh, lh and testosterone), perfusion and volume testicular (usg of testicles with doppler), spermogram, sexual changes, pain and quality of life (standard questionnaires).

Eligibility criteria:
inclusion criteria: * male * age between 19 and 60 years old * bilateral inguinal hernia * primary and reducible inguinal hernia exclusion criteria: * age less than 19 or more than 60 years old * asa \>iii * genito-urinary infection * immunodeficiency * history of testicular trauma2 * history of surgery or pelvic radiotherapy * history of testicular disease * fertility problems or sexual * illness that can be infertile * recurrent hernia * unilateral hernia * femoral or inguine-scrotal hernia * imprisoned hernia * use of gonadotrophins * use of anabolic steroids

Keywords: inguinal hernia infertility laparoscopy
m1 schizophrenia pet study

Conditions: Schizophrenia; Schizoaffective Disorder; Healthy

Summary: this exploratory study seeks to examine m1 receptor availability in sz patients and to relate m1 receptor availability to proximal and distal measures of cognitive performance, namely evoked ɣ oscillations in the eeg and verbal memory. furthermore, the relationship between hippocampal \[11c\]emo availability (bpnd), evoked ɣ oscillations, verbal memory, and measures of illness severity will be explored.

converging lines of evidence from postmortem studies provide strong evidence that brain muscarinic m1 receptor deficit is present in a subset of schizophrenia (sz) patients. m1 receptors are an important target for cognitive deficits in sz. however, until now, it has not been possible to examine the heterogeneity of sz with respect to m1 receptor availability in vivo. the development of a novel positron emission tomography (pet) ligand, \[11c\]emo, at yale pet center provides a unique opportunity to, for the first time, examine in vivo brain muscarinic m1 receptor availability in sz and, concurrently, elucidate the relationship of m1 receptors to cognitive deficits in sz. the investigators will compare m1 receptor availability in sz patients and age-, gender-matched healthy controls using \[11c\]emo and the high resolution research tomograph (hrrt), a pet scanner with high sensitivity and resolution available for human brain imaging. this study will explore the relationship between: hippocampal \[11c\]emo binding (as a measure of hippocampal m1 achr availability), encoding-related γ power during a verbal memory task, verbal memory, gender, and serum acetylcholine level. this exploratory study will provide the necessary pilot data to conduct a larger study to fully investigate the heterogeneity of sz with respect to m1 receptor availability.

Eligibility criteria:
inclusion criteria: * men and women aged 18- 65 years that are physically and mentally healthy with the exception of dsm-5 schizophrenia or schizoaffective disorder diagnosis * subjects with no metal in the body that may pose a risk during mri scanning * no significant medical history, including head trauma and bleeding disorders exclusion criteria: * men and women with a history or presence of clinically significant medical conditions * people who suffer from claustrophobia, have mri incompatible implants, or other contraindications for mri and pet scans

Keywords: schizophrenia muscarinic m1 receptor m1 achr [11c]emo pet scan mri scan
continuous hemoglobin evaluation

Conditions: Anemia

Summary: evaluate potential sources of error that affect the accuracy of continuous hemoglobin monitoring.


Eligibility criteria:
inclusion criteria: * patients undergoing elective surgery. exclusion criteria: * 0

Keywords: hemoglobin patient monitoring
comparative outcomes related to delivery-room cord milking in low-resourced kountries developmental follow up

Conditions: Hypoxic-Ischemic Encephalopathy; Birth Asphyxia

Summary: an extension of the cordmilk trial, the cordmilk follow-up trial will evaluate the neurodevelopmental outcomes at 22-26 months age of term/late preterm infants who were non-vigorous at birth and received umbilical cord milking (ucm) or early cord clamping (ecc).

the cordmilk follow-up trial will examine the difference in survival and neurodevelopmental impairment of infants who were non-vigorous at birth and enrolled in the cordmilk trial. the difference in survival and neurodevelopmental impairment in infants who received ucm and ecc will be assessed using standardized neurological and developmental assessment tools at 22-26 months of age.

Eligibility criteria:
inclusion criteria: * enrolled in cordmilk trial * non-vigorous at birth exclusion criteria: * none

Keywords: placental transfusion
eeg motor movement and imagery dataset for stroke

Conditions: Acute Stroke

Summary: the investigators collect and analyze the alpha and beta wave of eeg activity at the motor cortices of the participants, when the motor task is being performed. the brodmann area 10-20 method and portable eeg equipment was used in the single-center study.

to understand the motor mechanism of stroke patients with motor dysfunction, an eeg motor movement and imagery dataset for stroke will be created. 120 subjects will be enrolled in the single-center study. the investigators collect and analyze the eeg activity at the motor cortices of the participants, when the motor movement or imagery task is being performed. the alpha and beta wave of eegs were recorded from 32 electrodes as per the international 10-20 system with portable eeg equipment.

Eligibility criteria:
inclusion criteria: 1. the diagnosis of cerebral infarction conforms to the diagnostic criteria of chinese guidelines for the diagnosis and treatment of acute ischemic stroke 2018, and the diagnosis of intracerebral hemorrhage conforms to the diagnostic criteria of chinese guidelines for the diagnosis and treatment of intracerebral hemorrhage 2019. 2. first onset. 3. age ≥ 18 years old. 4. motor dysfunction of upper and / or lower limbs: muscle strength decreased by 0 to 5-grade and / or ataxia. 5. informed consent has been signed. exclusion criteria: 1. vital signs are unstable. 2. serious circulatory system, respiratory system, motor system and other diseases, such as atrial fibrillation, heart failure, pulmonary infection, severe liver and kidney insufficiency, lower extremity venous thrombosis and other serious diseases. 3. functional impairment of upper or lower limbs caused by other diseases of nervous system or other reasons, such as fracture, deformity, etc. 4. unable to cooperate to complete the examination, such as mental disorder, cognitive impairment, visual impairment, sitting balance disorder, etc 5. other reasons: alcoholism; skull defect; head skin defect, etc.
autologous hematopoietic stem cell transplantation combined with cd19-cart treatment of adult high-risk acute lymphoblastic leukemia

Conditions: Acute Lymphoblastic Leukemia ALL

Summary: to observe the efficacy and side effects of autologous hematopoietic stem cell transplantation combined with cd19-cart for adult acute lymphoblastic leukemia, and to evaluate the safety and efficacy of this regimen in the treatment of acute lymphoblastic leukemia.

to observe the efficacy and side effects of autologous hematopoietic stem cell transplantation combined with cd19-cart for adult acute lymphoblastic leukemia, and to evaluate the safety and efficacy of this regimen in the treatment of acute lymphoblastic leukemia.

Eligibility criteria:
inclusion criteria: * adult patients with high-risk acute b-lymphoblastic leukemia * complete remission was achieved after induction chemotherapy, and autologous cd19-car-t was successfully prepared * eligible for autologous hematopoietic stem cell transplantation * no major organ dysfunction exclusion criteria: * combined with malignant tumors of other organs * with a serious infection that is not under control * syphilis, aids, hepatitis b, hepatitis c, any one of them positive * patients who have had an allergic reaction to the drugs used in this study or similar drugs * other patients deemed unsuitable for inclusion by the investigators

Keywords: inaticabtagene autoleucel auto-hsct
augmenting growth hormone to ameliorate nonalcoholic fatty liver disease in adolescents

Conditions: NAFLD

Summary: fatty liver disease is an increasing problem in overweight and obese young adults. the purpose of this study is to test the effect of growth hormone on liver fat in obese young adults ages 18-29y with increased liver fat.

non-alcoholic fatty liver disease (nafld) is a significant health problem in obese adolescents. obese children and adolescents have significant reductions in growth hormone secretion, and we hypothesize that augmenting growth hormone in this population will decrease liver fat. growth hormone inhibits hepatic de novo lipogenesis, which is an important source of hepatic lipid. patients with pituitary gh deficiency have a higher prevalence of nafld and non-alcoholic steatohepatitis (nash) than the general population, and replacement of gh in these individuals reduces signs of liver damage. the purpose of this study is to test the hypothesis that growth hormone treatment will decrease liver fat quantity in young adults who begin the trial with more than 5% liver fat measured by magnetic resonance spectroscopy.

Eligibility criteria:
inclusion criteria: 1. males and females ages 18-29yo 2. bmi ≥95th percentile and/or ≥30kg/m\^2 3. hepatic fat ≥5% by hydrogen magnetic resonance spectroscopy (1h-mrs) 4. igf-1 standard deviation score (sds) \< 0 exclusion criteria: 1. alcohol consumption of \>14 drinks per week (females) or \>21 drinks per week (males) 2. use of insulin or oral anti-diabetic medications, or hemoglobin a1c (hba1c) \>7% or fasting glucose ≥126mg/dl 3. use of corticosteroid, gonadal steroids, or methotrexate ≤ 3 months prior to baseline visit 4. known diagnosis of alpha-1 antitrypsin deficiency, wilson's disease, hemochromatosis, or autoimmune hepatitis 5. hemoglobin \< 11.0 g/dl or weight \< 50kg 6. aspartate aminotransferase (ast) or alanine aminotransferase (alt) \>2.5x upper limit of normal (uln), total bilirubin \> uln, positive hepatitis b surface antigen (sag), or positive hepatitis c antibody 7. routine magnetic resonance imaging (mri) exclusion criteria (including weight \>450 pounds) 8. use of weight-loss medications or previous weight loss surgery 9. pregnant or breastfeeding, or, for sexually-active females, unwillingness to use an appropriate form of contraception during the study 10. known cirrhosis or clinical evidence of cirrhosis or portal hypertension on imaging or exam 11. use of growth hormone (gh) or growth hormone releasing hormone within the past 1 year 12. change in lipid lowering or anti-hypertensive medications within 3 months of screening 13. change in vitamin e or ursodiol \<6 months before screen; subjects on stable doses of vitamin e and/or ursodiol for ≥6 months will be eligible. 14. history of malignancy or active malignancy 15. history of hypopituitarism, head irradiation or any other condition or chronic illness known to affect the gh axis

Keywords: obesity adolescence fatty liver growth hormone
support group surveys for individuals who have type 1 diabetes and an eating disorder

Conditions: Eating Disorder; Type 1 Diabetes

Summary: we propose to conduct a monthly group of persons with type 1 diabetes who also withhold insulin. subjects will be asked to complete a 2-page survey (check-in sheet) at the beginning of each session and a 5-page survey (diabetes and eating disorders survey) on their first session and at their last session of their group.


Eligibility criteria:
inclusion criteria: * have an eating disorder * have type 1 diabetes * withhold their insulin * 18 years or older * actively being treated at edi * committed to at least one appointment each month with each member of their individual edi team (rd, cde or rn, cde; lp; and md) * approval of participation by edi/dm team (rd; rn; lp; md) * able to attend 66% of group sessions exclusion criteria: * psychologically not ready for this group therapy * have additional eating disorder issues that would make attendance in this group inappropriate * not committed to continuing treatment at pn's edi * not being actively treated at pn's edi * has type 2 diabetes
mrs and medication response: a pilot study

Conditions: Major Depressive Disorder; Major Depressive Episode; Major Depressive Disorder, Recurrent; Major Depression Mild; Major Depression Moderate; Major Depression Severe

Summary: we hope to demonstrate that magnetic resonance spectroscopy can detect brain concentration levels of paroxetine (paxil) or citalopram (celexa) or escitalopram (lexapro) in depressed patients.

the primary objective of this study is to demonstrate that it is feasible to image paroxetine (paxil) or citalopram (celexa) or escitalopram (lexapro) brain concentrations using mrs technology in depressed patients. the longer-term goal is to determine the relationship between clinically administered doses of paroxetine (paxil) or citalopram (celexa) or escitalopram (lexapro) (antidepressants), the amount of drug in the body via blood level, the concentrations of the drug achieved in brain measured via mrs, and genetics. it has been previously reported that individuals taking 20mg of paroxetine daily had brain paroxetine \[(paxil) levels via mrs ranging from 2-13 micromolar. similar or slightly higher ranges of brain drug concentrations have been reported for fluoxetine and fluvoxamine. since not all depressed patients respond to medications, one reason may be the amount of medication that crosses the blood-brain barrier. this may be influenced by genetic information. we want to examine these issues on a larger scale, but first we need to demonstrate that we can indeed determine paroxetine \[(paxil) or citalopram (celexa) or escitalopram (lexapro)\] levels via mrs. intended results analysis could not be conducted because a reliably sensitive spectroscopic method could not be developed.

Eligibility criteria:
major depressive disorder: inclusion criteria: 1. dsm diagnosis of major depressive disorder 2. taking paroxetine \[(paxil) or citalopram (celexa) or escitalopram (lexapro)\]for at least 6 weeks 3. between 21 - 75 years of age. 4. taking a stable dose of paroxetine \[(paxil) or citalopram (celexa) or escitalopram (lexapro)\] for at least the 2 weeks prior to the imaging session healthy controls: 1. between 21 - 75 years of age. 2. have a 21-item ham-d score of less than or equal to 5. 3. no current, or history of any axis i disorder. identify exclusion criteria. exclusion criteria are as follows: 1. contraindications for an mri exam. these includes biomedical devices such as pacemakers, aneurysm clips, prostheses, and other metallic objects embedded in the body such as bullets, buckshot, shrapnel, and any metal fragments from working around metal. 2. current pregnancy or lactation. 3. patients with claustrophobia. 4. history, or current axis i or axis ii disorders 5. active unstable medical problems, as confirmed by screening procedures 6. diagnosed with any autoimmune disease, (e.g., rheumatoid arthritis, lupus, mls). 7. chronic use of steroids or opiates. 8. positive urine toxicology screen for illicit substances of abuse.
a drug-drug interaction study of gk activator (2) and simvastatin in patients with type 2 diabetes.

Conditions: Diabetes Mellitus Type 2

Summary: this study will assess the potential pharmacokinetic interaction between gk activator (2) and simvastatin, and the potential effect of simvastatin on the glucose-lowering effect of gk activator (2) in patients with type 2 diabetes. patients will be randomized to one of 6 treatment sequences to receive single doses of a)gk activator (2) 100mg po, b)simvastatin 80mg po and c)gk activator (2) 100mg + simvastatin 80mg po. dosing will take place on study days 1, 8 and 15, and there will be a 7-14 day follow-up period after the last dose. the anticipated time on study treatment is \<3 months, and the target sample size is \<100 individuals.


Eligibility criteria:
inclusion criteria: * adult patients aged 18-75 years; * type 2 diabetes mellitus; * untreated, or taken off anti-diabetic or statin therapy \>=2 weeks before study start. exclusion criteria: * type 1 diabetes mellitus, or latent autoimmune diabetes in adults; * diabetic neuropathy, retinopathy or nephropathy; * patients treated with insulin or ppar gamma agonist within 6 weeks of screening.
benefits of a psychoeducation program for those awaiting treatment for ocd and ocd spectrum disorders

Conditions: Obsessive-Compulsive Disorder; Anxiety Disorders

Summary: this study will examine the effect of offering information sessions to a randomized group of patients with ocd spectrum disorders. psychoeducation is a component of first line treatment; though intended to be informative in nature, these psychoeducation services can have a positive effect on quality of life, sense of self-efficacy, functioning and a person's readiness to engage in long term treatment. however, no studies have dismantled and tested the independent effect of psychoeducation from standard treatment such as cognitive behavioural therapy. this study aims to directly test the potential effect of one aspect of cbt that if found to be helpful, can become a distinct early intervention component of care so that as people await services, they can profit from the early benefits associated with attending these information sessions. this study therefore sets out to examine the potential early benefits of providing education about the illness on symptom functioning, quality of life and readiness to engage in more formal treatment. we will offer 4 structured information sessions to individuals allocated to a wait list for services related to the treatment of ocd and ocd spectrum disorders in order to directly test the benefit of adding a didactic structured psychoeducation program to our services. the study will be a randomized trial where subjects (n=50) will be randomly assigned to receive either 1) 4 educational sessions covering information on diagnosis, treatment, available resources and self care for ocd and ocd spectrum disorders or 2) wait list as per usual with no additional information sessions. the experimental design is a 2 (treatment condition) by 2 (assessment phase) repeated measures factorial design. it is hypothesized that subjects participating in the psychoeducation group compared to the wait list control group will see greater reductions in self-reported measures of symptom severity and improvement in other measures of quality of life, level of functioning, self-efficacy and readiness to engage in treatment. if this study can demonstrate that the addition of a short structured informative intervention of 4 sessions can confer early benefits for those suffering with ocd and ocd spectrum disorders, then it provides another route by which patients can improve this condition specifically while waiting for consultation and the opportunity to receive a more structured, evidence-based treatment.


Eligibility criteria:
inclusion criteria: * referred for treatment services at the frederick w. thompson anxiety disorder centre at sunnybrook health sciences centre * presenting with ocd or ocd spectrum disorders * ability to communicate in written and spoken english exclusion criteria: * active substance abuse/dependence * suspected organic pathology * recent suicide attempt/active suicideality * active bipolar or psychotic disorder

Keywords: obsessive-compulsive disorder health education
vitrectomy and bevacizumab for diffuse diabetic macular edema

Conditions: Diffuse Diabetic Macular Edema

Summary: to evaluate combined effect of vitrectomy and bevacizumab to stabilize retinal thickness and visual acuity in patients with diffuse diabetic macular edema and their relation to renal disease.


Eligibility criteria:
inclusion criteria: * older than 25 yo * diffuse diabetic macular edema with or without previous treatment exclusion criteria: * another retinal disease * pregnancy

Keywords: edema retinal thickness diabetic retinopathy
synovial chondrosarcoma: a single institution experience

Conditions: Synovial Chondrosarcoma

Summary: single institution cases series review of histological, radiological and clinical data

single institution cases series review of histological, radiological and clinical data. investigators will retrieve from the archives of the rizzoli institute all the cases with a histological diagnosis of synovial chondrosarcoma.

Eligibility criteria:
inclusion criteria: * male and female patients treated at rizzoli institute from 01 january 1982 to 31 december 2017 * diagnosis of synovial chondrosarcoma * age ≥ 18 years * histological slides / formalin-fixed paraffin-embedded tissue tumor (ffpe) blocks from archive available to perform the histology analysis * written informed consent prior to any study-specific analysis and/or data collection exclusion criteria: * patients with histological diagnosis different from synovial chondrosarcoma
efficacy of treatment for generalized anxiety disorder

Conditions: Generalized Anxiety Disorder

Summary: the purpose of these questionnaires is to give us an overview of how gad has affected your life, and perhaps also to give us some clues about things that may have set you up to experience gad.

for us to evaluate the efficacy of our treatment programs, we are interested in your responses before and after treatment. we use two methods to evaluate the efficacy of our treatments: questionnaires and interviews with a member of the anxiety disorders clinic. as part of standard clinic procedure, each person in the program completes an in-person interview with a staff member who will determine your suitability for treatment. if you have received this questionnaire packet, it is likely that your concerns will be appropriately addressed in the anxiety disorders clinic. the purpose of the questionnaire packet is to assess the severity of your generalized anxiety disorder; its impact on your functioning, and factors that may contribute to the onset or maintenance of your gad (e.g., depression, intolerance of uncertainty). we will ask you to complete this questionnaire again when you have completed your treatment along with a brief telephone interview with a staff member of the anxiety disorders clinic.

Eligibility criteria:
inclusion criteria: * patients referred to the anxiety disorders clinic who receive a primary diagnosis of generalized anxiety disorder, and are accepted for treatment at the clinic. exclusion criteria: * individuals who either have not sought treatment for anxiety at the anxiety disorders clinic or patients who did not receive a primary diagnosis of generalized anxiety disorder.

Keywords: generalized anxiety disorder anxiety treatment efficacy